Ex vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in seborrheic keratosis lesions To the Editor: Seborrheic keratosis (SK) is one of the most common types of dermatologic lesions and is, therefore, the most common skin tumor seen by dermatologists in everyday practice. 1 Currently, cryosurgery is one of the most commonly employed and successful techniques to physically resolve an SK. 2 However, all patients are susceptible to some degree of blistering, infection, scarring, recurrence, and pigmentary changes after treatment, but darkerskinned individuals are particularly vulnerable to the last 3 adverse events. 3 To help predict the potential toxicologic impact of A-101, a recently Food and Drug Administrationeapproved topical 40% hydrogen peroxide solution for the treatment of SK, 4 compared with the gold standard cryosurgery, we evaluated skin architecture, metabolic activity, and cytotoxicity with a particular emphasis on melanocytes, using a validated ex vivo human reconstituted full thickness model derived from Fitzpatrick V skin (MRHE). 5 MRHEs were treated with cryosurgery (5-second and 10-second freeze cycles) or A-101 (1 L and 2 L) and analyzed by MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay, Fontana-Masson, TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), and S100 immunohistochemical staining to determine skin architecture, metabolic activity, and cytotoxicity. Histologic evaluation of untreated and A-101 vehicleetreated tissues revealed a normal stratum corneum, with spinous and basal cell layers overlying a well-organized dermis with scattered fibroblasts. MRHEs treated with cryosurgery for 5 s or 10 s both demonstrated overall thinning of the epidermis, with more pyknotic cells noted in the deeper spinous layer of the 10-second specimens. In both groups, dermal-epidermal junction separation was noted, though more prominent in the 10-second group. In both A-101etreated groups, acanthosis of the epidermis and mild pallor was noted, though not to the extent of the cryosurgery-treated specimens, without epidermal clefting (data not shown).
To (Fig 1, A) . Cellular metabolic activity was assessed using MTT assay, showing reduced metabolic activity indicative of reduced viability in cryosurgery-treated MRHE samples compared with A-101etreated groups (Fig 1, B) .
Within HPFs, untreated and vehicle-treated MRHEs were found to have 2.5 6 0.1987 melanocytes and 2.0 6 0.5000 melanocytes, respectively, based on S100 staining (Fig 1, C ) . After cryosurgery for 5 s and 10 s, the number of melanocytes were 0.45 6 0.1535 cells and 0.2 6 0.0918 cells, respectively, and after A-101 treatment for 1 L and 2 L, 1.95 6 0.1535 cells and 1.95 6 0.1535 cells, respectively.
Together, we show that cryosurgery is more cytotoxic than A-101, with special consideration of melanocyte survival. Our data suggests that A-101 might be a less caustic option for SK removal that reduces the risk of posttreatment pigmentary alterations. However, to best appreciate these findings, a clinical study that examines the risk for hypopigmentation or hyperpigmentation in darker skin types after A-101 treatment is warranted and is ongoing (ClinicalTrials.gov Identifier: NCT03224598).
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